vs

Side-by-side financial comparison of DXP ENTERPRISES INC (DXPE) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $527.4M, roughly 1.2× DXP ENTERPRISES INC). Royalty Pharma plc runs the higher net margin — 34.4% vs 4.3%, a 30.1% gap on every dollar of revenue. On growth, DXP ENTERPRISES INC posted the faster year-over-year revenue change (12.0% vs 4.8%). Over the past eight quarters, DXP ENTERPRISES INC's revenue compounded faster (13.1% CAGR vs 4.6%).

DXP Enterprises Inc. is a leading industrial distribution firm that provides maintenance, repair, operations (MRO) supplies, fluid handling equipment, pump systems and related technical services. It primarily serves customers in manufacturing, energy, mining, construction sectors, with core market coverage across North America.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

DXPE vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.2× larger
RPRX
$622.0M
$527.4M
DXPE
Growing faster (revenue YoY)
DXPE
DXPE
+7.2% gap
DXPE
12.0%
4.8%
RPRX
Higher net margin
RPRX
RPRX
30.1% more per $
RPRX
34.4%
4.3%
DXPE
Faster 2-yr revenue CAGR
DXPE
DXPE
Annualised
DXPE
13.1%
4.6%
RPRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DXPE
DXPE
RPRX
RPRX
Revenue
$527.4M
$622.0M
Net Profit
$22.8M
$214.2M
Gross Margin
31.6%
Operating Margin
8.8%
62.4%
Net Margin
4.3%
34.4%
Revenue YoY
12.0%
4.8%
Net Profit YoY
6.9%
2.9%
EPS (diluted)
$1.38
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DXPE
DXPE
RPRX
RPRX
Q4 25
$527.4M
$622.0M
Q3 25
$513.7M
$609.3M
Q2 25
$498.7M
$578.7M
Q1 25
$476.6M
$568.2M
Q4 24
$470.9M
$593.6M
Q3 24
$472.9M
$564.7M
Q2 24
$445.6M
$537.3M
Q1 24
$412.6M
$568.0M
Net Profit
DXPE
DXPE
RPRX
RPRX
Q4 25
$22.8M
$214.2M
Q3 25
$21.6M
$288.2M
Q2 25
$23.6M
$30.2M
Q1 25
$20.6M
$238.3M
Q4 24
$21.4M
$208.2M
Q3 24
$21.1M
$544.0M
Q2 24
$16.7M
$102.0M
Q1 24
$11.3M
$4.8M
Gross Margin
DXPE
DXPE
RPRX
RPRX
Q4 25
31.6%
Q3 25
31.4%
Q2 25
31.6%
Q1 25
31.5%
Q4 24
31.5%
Q3 24
30.9%
Q2 24
30.9%
Q1 24
30.0%
Operating Margin
DXPE
DXPE
RPRX
RPRX
Q4 25
8.8%
62.4%
Q3 25
8.5%
70.1%
Q2 25
9.2%
36.3%
Q1 25
8.5%
94.0%
Q4 24
8.3%
60.9%
Q3 24
8.4%
Q2 24
8.4%
50.2%
Q1 24
7.1%
-13.0%
Net Margin
DXPE
DXPE
RPRX
RPRX
Q4 25
4.3%
34.4%
Q3 25
4.2%
47.3%
Q2 25
4.7%
5.2%
Q1 25
4.3%
41.9%
Q4 24
4.5%
35.1%
Q3 24
4.5%
96.3%
Q2 24
3.7%
19.0%
Q1 24
2.7%
0.8%
EPS (diluted)
DXPE
DXPE
RPRX
RPRX
Q4 25
$1.38
$0.49
Q3 25
$1.31
$0.67
Q2 25
$1.43
$0.07
Q1 25
$1.25
$0.55
Q4 24
$1.28
$0.46
Q3 24
$1.27
$1.21
Q2 24
$1.00
$0.23
Q1 24
$0.67
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DXPE
DXPE
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$303.8M
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$498.4M
$9.7B
Total Assets
$1.7B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DXPE
DXPE
RPRX
RPRX
Q4 25
$303.8M
$618.7M
Q3 25
$123.8M
$938.9M
Q2 25
$112.9M
$631.9M
Q1 25
$114.3M
$1.1B
Q4 24
$148.3M
$929.0M
Q3 24
$35.0M
$950.1M
Q2 24
$49.9M
$1.8B
Q1 24
$139.7M
$843.0M
Total Debt
DXPE
DXPE
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
DXPE
DXPE
RPRX
RPRX
Q4 25
$498.4M
$9.7B
Q3 25
$488.3M
$9.6B
Q2 25
$468.1M
$9.5B
Q1 25
$444.7M
$9.8B
Q4 24
$422.8M
$10.3B
Q3 24
$402.4M
$10.3B
Q2 24
$384.7M
$9.8B
Q1 24
$375.5M
$9.9B
Total Assets
DXPE
DXPE
RPRX
RPRX
Q4 25
$1.7B
$19.6B
Q3 25
$1.4B
$19.3B
Q2 25
$1.4B
$18.3B
Q1 25
$1.4B
$17.6B
Q4 24
$1.3B
$18.2B
Q3 24
$1.2B
$18.0B
Q2 24
$1.2B
$17.7B
Q1 24
$1.2B
$16.1B
Debt / Equity
DXPE
DXPE
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DXPE
DXPE
RPRX
RPRX
Operating Cash FlowLast quarter
$37.8M
$827.1M
Free Cash FlowOCF − Capex
$34.5M
FCF MarginFCF / Revenue
6.5%
Capex IntensityCapex / Revenue
0.6%
Cash ConversionOCF / Net Profit
1.65×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$54.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DXPE
DXPE
RPRX
RPRX
Q4 25
$37.8M
$827.1M
Q3 25
$34.9M
$702.6M
Q2 25
$18.6M
$364.0M
Q1 25
$3.0M
$596.1M
Q4 24
$32.1M
$742.5M
Q3 24
$28.3M
$703.6M
Q2 24
$14.7M
$658.2M
Q1 24
$27.0M
$664.6M
Free Cash Flow
DXPE
DXPE
RPRX
RPRX
Q4 25
$34.5M
Q3 25
$28.1M
Q2 25
$8.3M
Q1 25
$-16.9M
Q4 24
$22.7M
Q3 24
$24.4M
Q2 24
$5.9M
Q1 24
$24.1M
FCF Margin
DXPE
DXPE
RPRX
RPRX
Q4 25
6.5%
Q3 25
5.5%
Q2 25
1.7%
Q1 25
-3.6%
Q4 24
4.8%
Q3 24
5.2%
Q2 24
1.3%
Q1 24
5.8%
Capex Intensity
DXPE
DXPE
RPRX
RPRX
Q4 25
0.6%
Q3 25
1.3%
Q2 25
2.1%
Q1 25
4.2%
Q4 24
2.0%
Q3 24
0.8%
Q2 24
2.0%
Q1 24
0.7%
Cash Conversion
DXPE
DXPE
RPRX
RPRX
Q4 25
1.65×
3.86×
Q3 25
1.61×
2.44×
Q2 25
0.79×
12.06×
Q1 25
0.14×
2.50×
Q4 24
1.50×
3.57×
Q3 24
1.34×
1.29×
Q2 24
0.88×
6.45×
Q1 24
2.38×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DXPE
DXPE

Service Centers$356.2M68%
Innovative Pumping Solutions$110.0M21%
Supply Chain Services$61.2M12%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons